Glukosaminsulfat og hyperkolesterolæmi

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-000541-11-DK

Enrollment

Registered

2005-02-21

Start date

2005-03-31

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Interventions

Trade Name: Glucosamin Pharma Nord Product Name: Glucosamin Pharma Nord Product Code: 460 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Glucosamine CAS Number: 3416-24-8 Concentration unit:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients do understand the studyprotocol (popular edition) Symptoms of osteoarthritis. 40 years or older. No intake of glucosamine for at least 3 months. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Severe illness (fx heart disease, cancer, inflammation illnesses as fx cronic Rheumatoid arthritis). Medicine (other than painkillers as paracetamol and NSAID) Change or planing a change in diet or physical activity Abuse of alcohol Pregnant or nursing Allergy to shellfish

Design outcomes

Primary

Measure	Time frame
Main Objective: Investigate the effect of glucosamine supplementation on lipoproteins (cholesterol) and triglycerides in patients with mild to moderate osteoarthritis.;Secondary Objective: Symptom change Adverse effects;Primary end point(s): Cholesterol and triglyceride concentration in the blood.	—

Countries

Denmark

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026